Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
6.370
Open
6.320
VWAP
6.21
Vol
6.16K
Mkt Cap
509.12M
Low
6.190
Amount
38.25K
EV/EBITDA(TTM)
15.49
Total Shares
69.58M
EV
516.74M
EV/OCF(TTM)
--
P/S(TTM)
2.58
Valneva SE is a France-based company that specializes in the development, manufacture and commercialization of vaccines to protect people from infectious diseases through preventative medicine. The Company's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by Enterotoxigenic escherichia coli (ETEC). The Company has also vaccines in development, including candidates against Lyme disease, COVID-19 and chikungunya. Its technologies and services segment cooperates with various pharmaceutical companies using its platform: EB66 vaccine production cell line and IC31 adjuvant. The Company is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products.
Show More
2 Analyst Rating
155.18% Upside
Wall Street analysts forecast VALN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VALN is 16.00 USD with a low forecast of 15.00 USD and a high forecast of 17.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
0 Hold
0 Sell
Moderate Buy
155.18% Upside
Current: 6.270
Low
15.00
Averages
16.00
High
17.00
155.18% Upside
Current: 6.270
Low
15.00
Averages
16.00
High
17.00
Guggenheim
Vamil Divan
Strong Buy
Maintains
$15 → $14
2025-05-08
Reason
Guggenheim
Vamil Divan
Price Target
$15 → $14
2025-05-08
Maintains
Strong Buy
Reason
HC Wainwright & Co.
Edward White
Strong Buy
Reiterates
$17
2025-04-15
Reason
HC Wainwright & Co.
Edward White
Price Target
$17
2025-04-15
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Edward White
Strong Buy
Reiterates
$17
2025-04-09
Reason
HC Wainwright & Co.
Edward White
Price Target
$17
2025-04-09
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Edward White
Strong Buy
Reiterates
$17
2025-04-02
Reason
HC Wainwright & Co.
Edward White
Price Target
$17
2025-04-02
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Edward White
Strong Buy
Reiterates
$17
2025-03-31
Reason
HC Wainwright & Co.
Edward White
Price Target
$17
2025-03-31
Reiterates
Strong Buy
Reason
Guggenheim
Dana Flanders
Strong Buy
Maintains
$17 → $15
2025-03-24
Reason
Guggenheim
Dana Flanders
Price Target
$17 → $15
2025-03-24
Maintains
Strong Buy
Reason
Guggenheim analyst Vamil Divan lowered the firm's price target on Valneva to $15 from $17 and keeps a Buy rating on the shares. The firm's lower target is mainly due to lowering its Ixchiq estimates given that product's slow launch, the analyst tells investors.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Valneva SE (VALN.O) is -8.92, compared to its 5-year average forward P/E of -226.36. For a more detailed relative valuation and DCF analysis to assess Valneva SE 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-226.36
Current PE
-8.92
Overvalued PE
459.75
Undervalued PE
-912.46
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-2.16
Current EV/EBITDA
-17.88
Overvalued EV/EBITDA
53.51
Undervalued EV/EBITDA
-57.82
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
Fair
5Y Average PS
3.90
Current PS
2.25
Overvalued PS
5.67
Undervalued PS
2.13
Financials
Annual
Quarterly
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
601.8K
Volume
2
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
VALN News & Events
Events Timeline
2025-05-07 (ET)
2025-05-07
11:53:04
Valneva says EMA started Ixchiq review after reports of SAEs
2025-04-14 (ET)
2025-04-14
11:49:10
Valneva granted marketing authorization for Ixchiq in Brail
2025-04-01 (ET)
2025-04-01
11:49:04
Valneva granted EC marketing authorization for Ixchiq vaccine
Sign Up For More Events
Sign Up For More Events
News
9.0
05-12BenzingaUS Health Agencies Recommend Pausing Valneva's Chikungunya Vaccine For Older Adults After Adverse Events
9.0
05-12NASDAQ.COMValneva: FDA Recommends Pause In Use Of IXCHIQ Vaccine In Elderly Individuals
9.0
05-12NewsfilterValneva Provides Update on Recommended Use of IXCHIQ® by Elderly Individuals in the United States
Sign Up For More News
People Also Watch
LNZA
Lanzatech Global Inc
0.264
USD
+1.93%
GTN
Gray Television Inc
4.040
USD
-1.70%
OBT
Orange County Bancorp Inc
26.840
USD
+0.26%
EXFY
Expensify Inc
2.370
USD
-0.84%
CPZ
Calamos Long/Short Equity & Dynamic Income Trust
15.620
USD
-0.38%
VPG
Vishay Precision Group Inc
26.790
USD
+3.28%
ATYR
aTyr Pharma Inc
3.270
USD
+9.00%
SFST
Southern First Bancshares Inc
37.010
USD
-1.17%
FSTR
L B Foster Co
19.400
USD
+0.78%
NODK
NI Holdings Inc
12.690
USD
-0.94%
FAQ
What is Valneva SE (VALN) stock price today?
The current price of VALN is 6.27 USD — it has increased 1.62 % in the last trading day.
What is Valneva SE (VALN)'s business?
What is the price predicton of VALN Stock?
What is Valneva SE (VALN)'s revenue for the last quarter?
What is Valneva SE (VALN)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Valneva SE (VALN)'s fundamentals?
How many employees does Valneva SE (VALN). have?